Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin treatment in children with autism and intellectual disability
2022-002423-36Phase 3Active
- Sponsor
- KU Leuven
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in Autism Spectrum Disorder (ASD) and intellectual disability (ID), sponsored by KU Leuven. Started Dec 2022; status: active.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)intellectual disability (ID)
Beyond the preview
Go deeper on 2022-002423-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002423-36.